Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) — Helocyte, Inc., (“Helocyte”) a subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO), announced today that data from a Phase 1 pilot trial (see NCT03560752) evaluating the potential safety, immunological response and efficacy of the cytomegalovirus (“CMV”) vaccine Triplex to enhance CMV protective immunity in immunosuppressed recipients of allogeneic hematopoietic […]
Allogeneic Stem Cell Transplant: Everything You Need to Know
What is allogeneic stem cell transplant? This is a question that many people are asking these days. Allogeneic stem cell transplant is a treatment option for cancer patients. It involves the infusion of healthy stem cells into the patient’s body in order to fight cancer. In this article, we will discuss all aspects of allogeneic […]